Related Experiment Videos
Ceftazidime pharmacokinetics in preterm newborns on the first day of life
Insights
Ceftazidime pharmacokinetic parameters were evaluated in preterm newborns. The antibiotic demonstrated good clinical and bacteriological response with no observed side effects.
Area of Science:
- Neonatal pharmacology
- Antibiotic pharmacokinetics
- Pediatric infectious diseases
Background:
- Preterm neonates exhibit altered drug pharmacokinetics due to physiological immaturity.
- Antibiotic selection and dosing in neonates require careful consideration of pharmacokinetic profiles.
- Ceftazidime is a third-generation cephalosporin used for serious bacterial infections.
Purpose of the Study:
- To characterize the pharmacokinetics of ceftazidime in preterm newborns.
- To assess the safety and efficacy of ceftazidime in this population.
- To inform optimal dosing strategies for ceftazidime in neonates.
Main Methods:
- Intramuscular administration of a 50 mg/kg ceftazidime dose to 13 preterm neonates within 24 hours of birth.
- Determination of key pharmacokinetic parameters (Cmax, Tmax, t1/2, AUC, Ke, Vd, CL) from serum concentrations.
- Clinical and bacteriological response assessment, alongside monitoring of biohumoral parameters.
Main Results:
- Key pharmacokinetic parameters were successfully determined.
- Ceftazidime treatment resulted in good clinical and bacteriological outcomes.
- No adverse side effects or significant alterations in biohumoral parameters were observed.
Conclusions:
- Ceftazidime exhibits favorable pharmacokinetic properties in preterm neonates.
- The drug is safe and effective for treating bacterial infections in this vulnerable population.
- Findings support the use of ceftazidime in neonatal care.
Abstract:
Ceftazidime pharmacokinetics were studied in 13 preterm newborns requiring antibiotic treatment, following intramuscular administration of a 50 mg/kg dose in the first 24 hours of life. The main pharmacokinetic parameters (peak concentration, time to reach peak, plasma half-life, area under the curve, elimination constant, distribution volume and plasma clearance) were determined directly from the serum concentrations observed. The clinical and bacteriological response to ceftazidime treatment was good; no side effects or alterations of biohumoral parameters were noted.